RespireRx Pharmaceuticals, founded with a mission to develop innovative drug therapies, focuses on treating sleep apnea and other neurological conditions. The company aims to improve patient outcomes through cutting-edge biopharmaceutical research. Their primary product, CX1739, is an AMPAkine designed to enhance respiratory function in sleep apnea patients and improve bladder function in individuals with spinal cord injuries.
Notable figures associated with RespireRx include leading researchers and industry experts in neurology and pharmacology. The company has secured significant funding, including a Department of Defense award for clinical studies on CX1739. RespireRx's preclinical research has shown promising results, positioning it as a key player in the biopharmaceutical sector with a potential to make substantial impacts on treating sleep apnea and related conditions.
